Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Harvard Bioscience (HBIO) Change in Acquisitions & Divestments (2024)

Harvard Bioscience (HBIO) has disclosed Change in Acquisitions & Divestments for 1 consecutive years, with $1.4 million as the latest value for Q3 2024.

Quarterly Change in Acquisitions & Divestments changed N/A to $1.4 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Jun 2025, down 26.12% year-over-year, with the annual reading at $1.9 million for FY2024, N/A changed from the prior year.
Change in Acquisitions & Divestments for Q3 2024 was $1.4 million at Harvard Bioscience, roughly flat from $1.4 million in the prior quarter.
The five-year high for Change in Acquisitions & Divestments was $1.4 million in Q2 2024, with the low at $495000.0 in Q1 2024.